CY1116164T1 - Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου - Google Patents

Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου

Info

Publication number
CY1116164T1
CY1116164T1 CY20151100321T CY151100321T CY1116164T1 CY 1116164 T1 CY1116164 T1 CY 1116164T1 CY 20151100321 T CY20151100321 T CY 20151100321T CY 151100321 T CY151100321 T CY 151100321T CY 1116164 T1 CY1116164 T1 CY 1116164T1
Authority
CY
Cyprus
Prior art keywords
methods
sulfathata
saminis
acetylgalactin
know
Prior art date
Application number
CY20151100321T
Other languages
Greek (el)
English (en)
Inventor
Minmin Qin
John M Henstrand
Gary N Zecherle
Dan J Wendt
Wai-Pan Chan
Lin Chen
Paul A Fitzpatrick
Christopher M Starr
Stuart Swiedler
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of CY1116164T1 publication Critical patent/CY1116164T1/el

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32Bonded phase chromatography
    • B01D15/325Reversed phase
    • B01D15/327Reversed phase with hydrophobic interaction
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3828Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CY20151100321T 2002-11-07 2015-04-03 Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου CY1116164T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/290,908 US6866844B2 (en) 2002-11-07 2002-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
EP10011421.4A EP2327414B1 (en) 2002-11-07 2003-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Publications (1)

Publication Number Publication Date
CY1116164T1 true CY1116164T1 (el) 2017-02-08

Family

ID=32312121

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100321T CY1116164T1 (el) 2002-11-07 2015-04-03 Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου

Country Status (17)

Country Link
US (1) US6866844B2 (enExample)
EP (2) EP2327414B1 (enExample)
JP (1) JP4459059B2 (enExample)
CN (1) CN100374157C (enExample)
AR (1) AR042019A1 (enExample)
AU (1) AU2003290642B2 (enExample)
BR (1) BRPI0316039B1 (enExample)
CA (1) CA2502928C (enExample)
CY (1) CY1116164T1 (enExample)
DK (1) DK2327414T3 (enExample)
ES (2) ES2533770T3 (enExample)
IL (1) IL168435A (enExample)
MX (1) MXPA05004880A (enExample)
PT (2) PT1565209E (enExample)
SI (1) SI2327414T1 (enExample)
TW (1) TWI327919B (enExample)
WO (1) WO2004043373A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972124B2 (en) * 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ES2366059T3 (es) * 2006-03-17 2011-10-14 Biomarin Pharmaceutical Inc. Ensayos para la detección de anticuerpos anti-enzimas lisosómicas.
CN101539550B (zh) * 2009-04-28 2012-05-23 李绍平 用于多糖的定性与定量分析方法
MX382443B (es) 2010-06-25 2025-03-11 Shire Human Genetic Therapies Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld).
PE20130589A1 (es) * 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
CN103068999A (zh) * 2010-08-20 2013-04-24 贝林格尔.英格海姆国际有限公司 通过在获自细胞培养物的液体中改变ph灭活蛋白酶的方法
US9896715B2 (en) 2011-12-20 2018-02-20 Jcr Pharmaceuticals Co., Ltd. Method for analyzing formyl glycine residue
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN105848746B (zh) * 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
TWI870412B (zh) * 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (enExample) 1961-07-20
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
SE387536B (sv) 1973-03-13 1976-09-13 Astra Laekemedel Ab Forfarande for framstellning av en lokalanestetisk beredning
AU5577101A (en) 2000-05-01 2001-11-12 Biomarin Pharmaceuticals Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly

Also Published As

Publication number Publication date
EP2327414B1 (en) 2015-01-07
BR0316039A (pt) 2005-09-13
ES2445028T3 (es) 2014-02-27
AR042019A1 (es) 2005-06-08
US20040101524A1 (en) 2004-05-27
ES2533770T3 (es) 2015-04-15
CN1726046A (zh) 2006-01-25
PT1565209E (pt) 2014-02-13
EP1565209A2 (en) 2005-08-24
PT2327414E (pt) 2015-04-13
CN100374157C (zh) 2008-03-12
HK1157215A1 (en) 2012-06-29
AU2003290642B2 (en) 2008-07-10
BRPI0316039B8 (enExample) 2021-05-25
CA2502928C (en) 2013-07-16
MXPA05004880A (es) 2005-07-22
BRPI0316039B1 (pt) 2017-08-29
CA2502928A1 (en) 2004-05-27
EP1565209A4 (en) 2008-01-02
DK2327414T3 (en) 2015-04-13
TWI327919B (en) 2010-08-01
US6866844B2 (en) 2005-03-15
WO2004043373A2 (en) 2004-05-27
WO2004043373A3 (en) 2004-08-05
TW200427459A (en) 2004-12-16
SI2327414T1 (sl) 2015-05-29
IL168435A (en) 2014-07-31
EP1565209B1 (en) 2013-11-06
JP4459059B2 (ja) 2010-04-28
AU2003290642A1 (en) 2004-06-03
EP2327414A1 (en) 2011-06-01
JP2006510356A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EA200500782A1 (ru) Лечение геморрагического шока
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR0012450A (pt) Benzimidazóis substituìdos
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
DE60331871D1 (de) Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
CY1110005T1 (el) Γρανζυμο β ως ενας επαγωγεας αποπτωσης κυτταρων ογκων εξαρτωμενος απο ενα hsp70/hsp70 πεπτιδιο
EA200400399A1 (ru) Способы лечения легочных заболеваний
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DE60322064D1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
PL1599211T3 (pl) Zastosowanie izorhamnetyny do leczenia nastrojów i chorób depresyjnych
DE60312154D1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
ATE415420T1 (de) Cxcl8-antagonisten
EA200501679A2 (ru) Фосфонатсодержащие противовоспалительные соединения (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ подавления воспалительной активности (варианты)
RU95108616A (ru) Способ лечения верхней ретро- или микрогнатии, осложненной расщелиной твердого неба и альвеолярного отростка